Patients With Crohn's Disease Treated With Certolizumab Pegol Experienced Long-Term Remission Regardless of Prior TNF-α Inhibitor Exposure (PRECiSE 4 Study)

被引：0
|
作者：
Sandborn, William J.
Schreiber, Stefan
Hanauer, Stephen B.
Colombel, Jean-Frederic
Bloomfield, Ralph
Lichtenstein, Gary
机构：
来源：
GASTROENTEROLOGY | 2010年 / 138卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
44
引用
收藏
页码：S9 / S9
页数：1
相关论文
共 50 条
  • [1] Long-Term Remission With Certolizumab Pegol in Crohn's Disease: Efficacy Over 4 Years in Patients With NO Prior TNF-α Inhibitor Exposure (PRECiSE 3 Study)
    Lichtenstein, Gary
    Thomsen, Ole O.
    Schreiber, Stefan
    Lawrance, Ian C.
    Hanauer, Stephen B.
    Bloomfield, Ralph
    Sandborn, William J.
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S165 - S165
  • [2] Long-term remission with certolizumab pegol in Crohn's disease: Efficacy over 4.5 years in patients with no prior TNF inhibitor exposure (PRECiSE 3 study).
    Lichtenstein, G.
    Thomsen, O.
    Schreiber, S.
    Lawrance, I
    Hanauer, S.
    Bloomfield, R.
    Sandborn, W.
    [J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 : S51 - S52
  • [3] Long-term Remission with Certolizumab Pegol in Crohn's Disease: Efficacy Over 4.5 Years in Patients with No Prior TNF Inhibitor Exposure (PRECiSE 3 Study)
    Lichtenstein, Gary
    Thomsen, Ole
    Schreiber, Stefan
    Lawrance, Ian
    Hanauer, Stephen
    Bloomfield, Ralph
    Sandborn, William
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S417 - S418
  • [4] Long-Term Remission With Certolizumab Pegol in Crohn's Disease: Efficacy Over 5 Years in Patients With No Prior Anti-TNF Agent Exposure (PRECiSE 3 Study)
    Sandborn, William J.
    Schwartz, David A.
    Schreiber, Stefan
    Lawrance, Ian C.
    Sen, David I.
    Lichtenstein, Gary R.
    [J]. GASTROENTEROLOGY, 2011, 140 (05) : S262 - S262
  • [5] Long-term remission with certolizumab pegol in Crohn's disease: Efficacy over 5 years in patients with no prior anti-TNF agent exposure (precise 3 study)
    Sandborn, William J.
    Schwartz, David
    Schreiber, Stefan
    Lawrance, Ian C.
    Sen, David
    Lichtenstein, Gary R.
    [J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 : S23 - S23
  • [6] Improvement in Quality of Life as a Predictor of Long-Term Remission in Crohn's Disease Patients Treated with Certolizumab Pegol
    Feagan, Brian
    Schreiber, Stefan
    Spearman, Marshall
    Kosutic, Gordana
    Hasan, Iram
    Coarse, Jason
    Sandborn, William
    [J]. INFLAMMATORY BOWEL DISEASES, 2016, 22 : S41 - S41
  • [7] Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol
    Melmed, Gil Y.
    McGovern, Dermot
    Schreiber, Stefan
    Kosutic, Gordana
    Spearman, Marshall
    Coarse, Jason
    Sandborn, William J.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (12) : 1937 - 1941
  • [8] Predictors of Maintenance of Long-term Remission in Crohn's Disease Patients Treated With Certolizumab Pegol: Multivariate and Univariate Analyses From the PRECiSE 3 Study
    Sandborn, William
    Schreiber, Stefan
    Siegel, Corey
    Melmed, Gil
    McGovern, Dermot
    Pierre-Louis, Bosny
    Kosutic, Gordana
    Spearman, Marshall
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S514 - S514
  • [9] Early Remission Status As a Predictor of Long-Term Outcome in Crohn's Disease Patients Treated With Certolizumab Pegol: Results of an Analysis From the PRECiSE 3 Study
    Melmed, Gil
    McGovern, Dermot
    Schreiber, Stefan
    Kosutic, Gordana
    Spearman, Marshall
    Coarse, Jason
    Sandborn, William
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S252 - S252
  • [10] Long-term remission with certolizumab pegol in Crohn's disease over 3.5 years: results from the PRECiSE 3 study
    Lichtenstein, G.
    Thomsen, O.
    Schreiber, S.
    Lawrance, I
    Hanauer, S.
    Bloomfield, R.
    Sandborn, W.
    [J]. INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : S12 - S13
12345